DRG biosimilar experts routinely analyze key market events via a presentation and commentary, available for play-back anytime.

Table of contents

  • Market Event Analysis
    • Event Analysis
      • The FDA's New Guidance on Insulin Biosimilar Development
        • December 17, 2019
        • December 17, 2019
      • Increasing Insurer Coverage of Biosimilars in the United States
        • August 27, 2019
        • August 27, 2019
      • The Future Impact of Authorized Generics on the Biologics Market
        • June 20, 2019
        • June 20, 2019
      • The Race for Pegfilgrastim Biosimilars in the United States and Europe
        • September 5, 2018
        • September 5, 2018
      • Approval of the First ESA Biosimilar in the United States
        • June 25, 2018
        • June 25, 2018
      • Ontruzant's EC Approval
        • April 19, 2018
        • April 19, 2018
      • AbbVie Settles with Amgen on Humira Patents
        • October 6, 2017
        • October 6, 2017
      • A Step Forward for Oncology Monoclonal Antibody Biosimilars
        • October 2, 2017
        • October 2, 2017
      • Coherus's CHS-1701 Rejected by the FDA
        • June 22, 2017
        • June 22, 2017 (Webinar)
      • The EC Approval of Celltrion's Truxima
        • February 27, 2017
        • February 27, 2017 (Webinar)
      • FDA Approves the First Etanercept Biosimilar: Sandoz's Erelzi
        • September 1, 2016
        • September 1, 2016 Webinar
      • Remaining U.S. Roadblocks to Inflectra Adoption Postapproval
        • May 23, 2016
        • May 23, 2016 (Webinar)
      • Ten Years of Biosimilars: Insights from the 14th Annual Biosimilar Medicines Group Congress
        • May 19, 2016
        • May 19, 2016 (Webinar)
      • Highlights from the 8th Biosimilars Congregation
        • March 24, 2016
        • March 24, 2016 (Webinar)
      • The EMA Approval of Samsung Bioepis's Benepali
        • January 25, 2016
        • January 25, 2016 (Webinar)

Author(s): Hamzah Aideed, MSc; Jimmy Jacob; Marta Delgado, PhD

Hamzah Aideed is a Principal Analyst in the biosimilars team at Decision Resources Group. Hamzah’s responsibilities include conducting primary and secondary market research, generating key insights into biosimilars and the biopharmaceutical industry, and providing client support. His work in biosimilars encompasses four key therapy areas – immunology, oncology, endocrinology, and nephrology. Prior to joining DRG, Hamzah was a Senior Research Executive at Consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies, for bespoke ad-hoc consulting projects. He holds an in Biotechnology & Business Management from the University of Warwick and a in Biological Chemistry from Aston University.  

Jimmy Jacob, is a Business Insights Analyst in the Biosimilars team. Prior to joining DRG, Jimmy worked as a Scientist in Medimmune and Horizon Discovery mostly involving CRIPSR/Cas9 therapeutics. He received his master’s degree in Biotechnology from University of Dundee and his from Imperial College London. His work involved identifying novel molecules that regulated oestrogen receptor-alpha in breast cancer.

Marta Delgado, is a Business Insight Analyst in the Biosimilars Research team, responsible for the analysis of the biosimilars market across four main therapeutic areas – oncology, endocrinology, immunology and nephrology. Marta holds a in Molecular Neuroscience from University College of London (UCL) and a in Biomedicine from University Pompeu Fabra (UPF), Barcelona. Prior to joining the Biosimilars Research team, Marta worked as a Research Analyst at SKIM, specialising in advanced quantitative studies assessing the potential market opportunities to support life sciences companies in their business decision making.